Compare Cytokinetics Inc (CYTK) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs CarMax, Inc — how do they compare? Cytokinetics Inc trades at $81.96 (market cap $11.12B), while CarMax, Inc trades at $55.75 (market cap $7.91B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Cytokinetics Inc is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals.
| CYTK | KMX | |
|---|---|---|
Market Cap | $11.12B | $7.91B |
Sector | Technology | Consumer Cyclical |
52-Week High | $87.26 | $63.53 |
52-Week Low | $33.23 | $30.88 |
Enterprise Value | $11.59B | $26.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
CarMax (KMX) trades at $54.87, up 2.58% today, with a bullish technical signal from moving averages and a neutral oscillator stance. The company reported Q1 2026 earnings that beat expectations, with EPS of $0.34 versus $0.23 expected, driven by cost controls and strategic execution. Revenue for 2025 was $26.35 billion, with net income of $500.56 million, though margins remain thin. Recent news highlights a four-pillar turnaround strategy under new CEO Keith Barr, with insider buying and positive analyst updates supporting sentiment.
The outlook for KMX hinges on successful execution of its growth strategy amid competitive pressures and margin challenges. While technical indicators suggest near-term strength, fundamental risks include high debt levels and fluctuating profitability. Analyst consensus is cautious with a hold-heavy rating, but the stock offers potential for recovery if operational improvements sustain. Investors should weigh the bullish technical setup against fundamental headwinds and ongoing investigations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
